Zymeworks posts investor presentation on planned Theravance Biopharma acquisition for YUPELRI cash flows

Theravance Biopharma Inc

TBPH

0.00

Zymeworks Inc.

ZYME

0.00

Zymeworks agreed to acquire Theravance Biopharma for USD 929 million; expected closing in 2H26.
Funding includes USD 350 million non-recourse notes from OMERS Life Sciences; coupon 8.25%; maturity 2036; collateral tied to YUPELRI assets.
Zymeworks cash at risk set at USD 219 million; structure targets no equity issuance.
Deal centers on Theravance’s 35% YUPELRI profit share; presentation pegs annual profit share at about USD 60 million at current run-rate.
YUPELRI 2025 U.S. net sales listed at USD 266.6 million; 2025 growth 12%; generics settlements point to April 2039 licensed launch dates.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zymeworks Inc. published the original content used to generate this news brief on June 29, 2026, and is solely responsible for the information contained therein.

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.